facemask

COVID-19 pandemic likely to last two years, study says

pharmafile | May 1, 2020 | News story | Medical Communications COVID-19, coronavirus, pandemic 

The coronavirus pandemic is likely to last as long as two years and will not be properly controlled until two-thirds of the world’s populations have become immune.

This is according to a report titled “COVID-19: The CIDRAP Viewpoint” created by the Center for Infectious Disease Research and Policy (CIDRAP).

The study outlines how that COVID-19’s ability to spread from people who don’t appear to be sick makes it far more difficult to control than influenza. Research indicates that people may even be more infectious before they display symptoms.

CIDRAP says that: “Risk communication messaging from government officials should incorporate the concept that this pandemic will not be over soon and that people need to be prepared for possible periodic resurgences of disease over the next two years.

“We must be prepared for at least another 18 to 24 months of significant COVID-19 activity, with hot spots popping up periodically in diverse geographic areas. The course of the pandemic also could be influenced by a vaccine; however, a vaccine will likely not be available until at least sometime in 2021. And we don’t know what kinds of challenges could arise during vaccine development that could delay the timeline.”

The report also recommends that the US prepare for a worst case scenario that includes a second big wave of infections during the Autumn and Winter.

Many companies are working quickly to develop a vaccine with estimates an effective compound could be developed by the end of the year. But as the CIDRAP report highlights, a vaccine being ready for safe use in humans is still at least a year away.

Conor Kavanagh

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …

Latest content